{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T13:46:49Z","timestamp":1769348809011,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to examine trends in the first\u2010year pharmacological treatment of newly treated schizophrenia patients in Taiwan between 1999 and 2006.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We collected data from the National Health Insurance Research Database of all newly treated patients with a diagnosis of schizophrenia\u2010spectrum disorder (ICD\u20109 295.x). We analyzed all prescription records after diagnosis of schizophrenia and described the patterns of antipsychotics use, other concomitant psychotropic agents use, and mental health system utilization. We tested for trend using multivariate logistic regression and Spearman's partial correlation rank test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2895 newly treated patients with schizophrenia were enrolled. The percentage of prescriptions of second\u2010generation antipsychotics (SGAs) was found to have increased significantly, from 27.5% in 1999 to 76.9% in 2006. The ratio of good antipsychotics adherence (medication possession ratio &gt;0.8) also increased, from 23.2% in 1998 to 38.9% in 2006. Corresponding to this, the percentage of usage of first\u2010generation antipsychotic drugs, anticholinergic agents, and long\u2010term combination therapy declined. However, the prescription of antidepressants and mood stabilizers and the hospitalization rate increased. No change was noted in the number of psychiatric visits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the first\u2010year treatment of newly treated schizophrenic patients between 1999 and 2006, we found pharmacological treatment had changed in terms of types of antipsychotics, adherence, and the use of other concomitant psychotropic agents, with the introduction of SGAs. The benefits and costs of the changes with a trend toward an increasing prescription of SGAs warrant further investigation. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3254","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T04:22:38Z","timestamp":1331698958000},"page":"989-996","source":"Crossref","is-referenced-by-count":15,"title":["Trends in treatment of newly treated schizophrenia\u2010spectrum disorder patients in Taiwan from 1999 to 2006"],"prefix":"10.1002","volume":"21","author":[{"given":"Chi\u2010Shin","family":"Wu","sequence":"first","affiliation":[{"name":"Far Eastern Memorial Hospital Department of Psychiatry  Ban\u2010Chiao Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Ju","family":"Lin","sequence":"additional","affiliation":[{"name":"Far Eastern Memorial Hospital Department of Psychiatry  Ban\u2010Chiao Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung","family":"Feng","sequence":"additional","affiliation":[{"name":"Far Eastern Memorial Hospital Department of Psychiatry  Ban\u2010Chiao Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"The Global Burden of Disease","author":"World Health Organization","year":"2004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.248"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.4.692"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.4.700"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L155"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial","volume":"57","author":"Chakos MH","year":"2006","journal-title":"Psychiatr Serv"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.06.003"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10673220590923164"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1115"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.01.015"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007025"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2004.01311.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.62.8.908"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181e049ca"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_8_19_1","volume-title":"Guidelines for ATC Classification and DDD Assignment","author":"WHO Collaborating Centre for Drug Statistic Methodology","year":"2009"},{"key":"e_1_2_8_20_1","first-page":"73","article-title":"Non\u2010Parametric Partial Association Revisted","volume":"40","author":"Schemper M","year":"1991","journal-title":"J Roy Stat Soc D\u2010Sta"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a006928"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00947.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.1.103"},{"key":"e_1_2_8_24_1","first-page":"CD001162","article-title":"Sulpiride for schizophrenia","volume":"2","author":"Soares BG","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_25_1","first-page":"CD008125","article-title":"Sulpiride augmentation for schizophrenia","volume":"1","author":"Wang J","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1013"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn018"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002270"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.6.714"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.1006e12"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.975"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.51.5.634"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.9.1379"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0386-1"},{"key":"e_1_2_8_35_1","unstructured":"The Department of Health Executive Yuan R.O.C.(Taiwan).http:\/\/www.doh.gov.tw\/CHT2006\/DM\/DM2_2.aspx?now_fod_list_no=10144&class_no=440&level_no=4[January 13 2012]."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.05.006"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.61.5.483"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.5.625"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3254","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:11:40Z","timestamp":1695510700000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/pds.3254"],"URL":"https:\/\/doi.org\/10.1002\/pds.3254","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}